Need Help?
Email Course Coordinator

The Record from Prous Science Drug Data Report (File 452)

We'll look first at Prous Science Drug Data Report (File 452). What we see first when we retrieve the vatalanib record from File 452 is that a structure image is available.

I think I'll look at the basic drug pipeline data to see how the Prous Science Drug Data Report data differs from some of the other files; then I'll send it along to Sharon for review.

1. Drug/Product Name: Prous Science Drug Data Report has different fields for chemical names, generic names and synonyms. Usually you will also find brand names and company code names. The CAS® Registry Number is available for this drug too.
2. Company Names: generally lists parent names along with subsidiaries for originators (does not distinguish which name is which), and is less thorough in its identification of licensees.
3. Licensees: contains the manufacturers or other nonindustrial sources that have entered into a license agreement with the originator of the compound. Tip 5-2
4. Chemical structure images: available as part of the record
5. Developmental Status: no development history is available, nor are precise dates given other than the year of the highest phase. File 452 identifies only the highest phase reached worldwide, with no linkage to indication(s) and no mention of target market. Tip 5-3
6. Therapeutic Classification: File 452 uses its own classification system, a mixture of therapeutic and pharmacological categories Tip 5-4 Tip 5-5

After reviewing the record below, go to the next page.

Note: In order to give you supplemental information (tips, learn more comments) about the Dialog record, we have had to add spaces between some of the fields. Print out the complete record for File 452 to have a concise duplicate of the Dialog record you will retrieve online. You can compare it to the parts of the record we will highlight later in the lesson.

 1/19/1
DIALOG(R)File 452: Drug Data Report
(c) 2007 Prous Science. All rights reserved.


00271217 
Entry Number:   271217 
     (Actively Investigated) 
Compound Type:   Preferred 
Drug Name:   CGP-79787 (free base)
      CGP-79787D 
      PTK-787 
      PTK/ZK 
      ZK-222584 
Generic Name:   Vatalanib
succinate (recommended INNM; USAN) 
Chemical Name:   N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-
1-amine succinate 
Formula:   C24H21CLN4O4 
CAS Registry No.:   212142-18-2
      212141-51-0 (diHCl) 
      212141-52-1 (hydrochloride) 
      212141-54-3 (free base) 
      212141-89-4 (fumarate) 
      212141-90-7 (methanesulfonate) 
      212142-19-3 (oxalate salt) 



Development Phase:   Phase III 
Originator:   National Cancer Institute (US)
      Nihon Schering Novartis 
      Schering AG 
Class:   16500 (Treatment of Age-Related Macular Degeneration) 
      75016 (Astrocytoma Therapy) 
      75019 (Glioblastoma Multiforme Therapy)
      75020 (Breast Cancer Therapy)
      75025 (Colorectal Cancer Therapy)
      75036 (Kaposi's Sarcoma Therapy)
      75042 (Myeloid Leukemia Therapy)
      75046 (Lung Cancer Therapy)
      75047 (Non-Small Cell Lung Cancer Therapy)
      75056 (Multiple Myeloma Therapy)
      75057 (Myelodysplastic Syndrome Therapy)
      75063 (Pancreatic Cancer Therapy)
      75065 (Prostate Cancer Therapy)
      75070 (Renal Cancer Therapy)
      75080 (Solid Tumors Therapy)
      75751 (Angiogenesis Inhibitors)
      75855 (Inhibitors of Signal Transduction Pathways) 
Previously Published in:   Drug Data Report, Vol. 21, No. 2, p. 175, 1999 
      Drug Data Report, Vol. 22, No. 2, p. 188, 2000
      Drugs of the Future, Vol. 27, No. 1, p. 43, 2002

Go to the next page.